Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial

RATIONALE: Lumacaftor/ivacaftor (LUM/IVA) was shown to be safe and well tolerated in children 2 through 5 years of age with cystic fibrosis (CF) homozygous for F508del-CFTR in a Phase 3 open-label study. Improvements in sweat chloride concentration, markers of pancreatic function, and lung clearance...

Descripción completa

Detalles Bibliográficos
Autores principales: Stahl, Mirjam, Roehmel, Jobst, Eichinger, Monika, Doellinger, Felix, Naehrlich, Lutz, Kopp, Matthias V., Dittrich, Anna-Maria, Lee, Christopher, Sommerburg, Olaf, Tian, Simon, Xu, Tu, Wu, Pan, Joshi, Aniket, Ray, Partha, Duncan, Margaret E., Wielpütz, Mark O., Mall, Marcus A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405608/
https://www.ncbi.nlm.nih.gov/pubmed/36943405
http://dx.doi.org/10.1513/AnnalsATS.202208-684OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405608/
https://www.ncbi.nlm.nih.gov/pubmed/36943405
http://dx.doi.org/10.1513/AnnalsATS.202208-684OC

Ejemplares similares